About me

I am currently a principal scientist in early discovery at Bristol Myers Squibb (San Diego), where I co-lead strategy for the Induced Proximity Innovation group. My work spans early discovery, from target prioritization and program initiation through proof-of-concept studies, structure-activity relationships, and go/no-go decision-making. I currently also lecture at the University of Maryland School of Pharmacy on therapeutic modalities.

Prior to Bristol Myers Squibb, I worked as a scientist in antibody discovery at the Chan Zuckerberg Biohub (San Francisco). Before entering industry, my academic research at Stanford focused on understanding macromolecular mechanisms and the structure and function of biological macromolecules. While at Stanford, I also co-founded a small biotech investment fund and led an early antiviral therapeutics effort (ViRelieve).

Focus and Interests

I’m deeply interested in drug discovery and focus on applying quantitative, mechanistic thinking to accelerate early discovery and reduce scientific risk, especially at key decision points: what to prioritize, the shortest path to a go/no-go decision, and what to deprioritize.

In practice, that means I focus on:

• Therapeutic modalities: understanding modality advantages and limitations, Mechanism of action, modality–target fit, and differentiation.

• Technical risk and uncertainty: making assumptions explicit, weighing risk vs upside, and clarifying what would have to be true for a program to work.

• De-risking strategy: identifying the most decisive experiments and milestones that reduce uncertainty quickly and support clear go/no-go decisions.

• Translating science to value: connecting modality specifics and early discovery risk to de-risking plans and milestones that accelerate go/no-go decisions.